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FANCG 637-643 DELETION MUTATION: FREQUENCY IN BLACK PATIENTS WITH 
ACUTE MYELOID LEUKAEMIA OR APLASTIC ANAEMIA AND THE CLINICAL 




Fanconi anaemia (FA) is an autosomal recessive disorder characterised by aplastic 
anaemia (AA) and a high risk of developing acute myeloid leukaemia (AML).  It is 
unknown whether heterozygote carriers are also predisposed to developing these 
disorders. 
 
The black South African population group is ideal for FA mutation screening because 
the presence of a founder mutation, FANCG 637-643, makes screening relatively 
straight forward.  Three individuals with AML (115 screened) and one with AA (78 
screened) were found to be heterozygous for the black South African founder 
mutation.  From our data it seems unlikely that this mutation places heterozygous 
carriers of the mutation at high risk of developing AML or AA.  Three children with 
AA out of 26 screened, were homozygous for the mutation.  This finding reiterates the 
importance of screening all children with AA for FA. 
 
The frequency of certain congenital abnormalities in black South African FA patients 
was compared to patients described by other research groups.  The frequencies of the 
abnormalities were similar to other FANCG cohorts described but significant 
differences to a group of FA patients from unspecified complementation groups were 
found.  This difference could be because different complementation groups are 
associated more or less strongly with specific abnormalities.   
 
  
It was found previously that particular congenital abnormalities in FA patients are 
associated with a poor haematological outcome.  We concluded that black South 
African FANCG patients have a high risk of early development of AA even though 
they do not have a high frequency of congenital abnormalities.   
 
